vs
BGSF, INC.（BGSF）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
BGSF, INC.的季度营收约是STANDARD BIOTOOLS INC.的1.1倍（$22.0M vs $19.6M），BGSF, INC.净利率更高（-5.3% vs -177.4%，领先172.1%），BGSF, INC.同比增速更快（-9.4% vs -11.5%），BGSF, INC.自由现金流更多（$1.7M vs $-23.1M），过去两年BGSF, INC.的营收复合增速更高（-5.3% vs -12.2%）
BGSF Inc.是一家总部位于美国的领先人力资源解决方案提供商，提供定制化人员派遣、人才招聘和全流程劳动力管理服务，覆盖信息技术、医疗健康、专业行政、轻工业、创意产业等核心领域，服务北美各规模的企业客户。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
BGSF vs LAB — 直观对比
营收规模更大
BGSF
是对方的1.1倍
$19.6M
营收增速更快
BGSF
高出2.1%
-11.5%
净利率更高
BGSF
高出172.1%
-177.4%
自由现金流更多
BGSF
多$24.8M
$-23.1M
两年增速更快
BGSF
近两年复合增速
-12.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $22.0M | $19.6M |
| 净利润 | $-1.2M | $-34.7M |
| 毛利率 | 35.0% | 48.5% |
| 营业利润率 | -17.6% | -168.5% |
| 净利率 | -5.3% | -177.4% |
| 营收同比 | -9.4% | -11.5% |
| 净利润同比 | -18.2% | -28.8% |
| 每股收益（稀释后） | $-0.12 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BGSFLAB
| Q4 25 | $22.0M | — | ||
| Q3 25 | $26.9M | $19.6M | ||
| Q2 25 | $23.5M | $21.8M | ||
| Q1 25 | $20.9M | $40.8M | ||
| Q4 24 | $24.3M | — | ||
| Q3 24 | $29.8M | $22.1M | ||
| Q2 24 | $25.7M | $22.5M | ||
| Q1 24 | $24.5M | $45.5M |
净利润BGSFLAB
| Q4 25 | $-1.2M | — | ||
| Q3 25 | $-5.8M | $-34.7M | ||
| Q2 25 | $-3.7M | $-33.5M | ||
| Q1 25 | $-722.0K | $-26.0M | ||
| Q4 24 | $-981.0K | — | ||
| Q3 24 | $-804.0K | $-26.9M | ||
| Q2 24 | $-761.0K | $-45.7M | ||
| Q1 24 | $-792.0K | $-32.2M |
毛利率BGSFLAB
| Q4 25 | 35.0% | — | ||
| Q3 25 | 35.9% | 48.5% | ||
| Q2 25 | 35.8% | 48.8% | ||
| Q1 25 | 36.2% | 48.4% | ||
| Q4 24 | 35.9% | — | ||
| Q3 24 | 35.9% | 54.9% | ||
| Q2 24 | 37.3% | 46.1% | ||
| Q1 24 | 38.1% | 53.1% |
营业利润率BGSFLAB
| Q4 25 | -17.6% | — | ||
| Q3 25 | -3.5% | -168.5% | ||
| Q2 25 | -18.8% | -118.1% | ||
| Q1 25 | 1.6% | -80.8% | ||
| Q4 24 | -15.7% | — | ||
| Q3 24 | -3.4% | -120.9% | ||
| Q2 24 | -5.7% | -134.5% | ||
| Q1 24 | 1.7% | -132.2% |
净利率BGSFLAB
| Q4 25 | -5.3% | — | ||
| Q3 25 | -21.6% | -177.4% | ||
| Q2 25 | -15.9% | -153.7% | ||
| Q1 25 | -3.5% | -63.8% | ||
| Q4 24 | -4.0% | — | ||
| Q3 24 | -2.7% | -122.0% | ||
| Q2 24 | -3.0% | -203.3% | ||
| Q1 24 | -3.2% | -70.6% |
每股收益（稀释后）BGSFLAB
| Q4 25 | $-0.12 | — | ||
| Q3 25 | $-0.52 | $-0.09 | ||
| Q2 25 | $-0.34 | $-0.09 | ||
| Q1 25 | $-0.06 | $-0.07 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.07 | $-0.07 | ||
| Q2 24 | $-0.07 | $-0.12 | ||
| Q1 24 | — | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $48.1M | $399.7M |
| 总资产 | $57.8M | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BGSFLAB
| Q4 25 | — | — | ||
| Q3 25 | $41.2M | $129.4M | ||
| Q2 25 | $2.8M | $158.6M | ||
| Q1 25 | $2.0M | $150.9M | ||
| Q4 24 | $32.0K | — | ||
| Q3 24 | $262 | $210.6M | ||
| Q2 24 | $226 | $269.8M | ||
| Q1 24 | $50 | $287.1M |
总债务BGSFLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益BGSFLAB
| Q4 25 | $48.1M | — | ||
| Q3 25 | $50.7M | $399.7M | ||
| Q2 25 | $78.3M | $424.5M | ||
| Q1 25 | $81.8M | $454.6M | ||
| Q4 24 | $82.3M | — | ||
| Q3 24 | $82.9M | $489.3M | ||
| Q2 24 | $83.2M | $510.3M | ||
| Q1 24 | $83.6M | $577.3M |
总资产BGSFLAB
| Q4 25 | $57.8M | — | ||
| Q3 25 | $83.6M | $539.6M | ||
| Q2 25 | $149.7M | $557.0M | ||
| Q1 25 | $152.3M | $579.6M | ||
| Q4 24 | $150.1M | — | ||
| Q3 24 | $157.3K | $681.5M | ||
| Q2 24 | $159.8K | $708.7M | ||
| Q1 24 | $170.6K | $777.7M |
负债/权益比BGSFLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.7M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $1.7M | $-23.1M |
| 自由现金流率自由现金流/营收 | 7.6% | -118.1% |
| 资本支出强度资本支出/营收 | 0.1% | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-16.0K | $-111.1M |
8季度趋势，按日历期对齐
经营现金流BGSFLAB
| Q4 25 | $1.7M | — | ||
| Q3 25 | $-4.8M | $-22.2M | ||
| Q2 25 | $2.2M | $-20.7M | ||
| Q1 25 | $1.1M | $-30.3M | ||
| Q4 24 | $3.2M | — | ||
| Q3 24 | $6.5M | $-27.9M | ||
| Q2 24 | $7.3M | $-39.0M | ||
| Q1 24 | $7.4M | $-62.5M |
自由现金流BGSFLAB
| Q4 25 | $1.7M | — | ||
| Q3 25 | $-4.9M | $-23.1M | ||
| Q2 25 | $2.1M | $-22.6M | ||
| Q1 25 | $1.0M | $-35.3M | ||
| Q4 24 | $2.5M | — | ||
| Q3 24 | $6.5M | $-30.1M | ||
| Q2 24 | $7.3M | $-41.0M | ||
| Q1 24 | $6.9M | $-63.3M |
自由现金流率BGSFLAB
| Q4 25 | 7.6% | — | ||
| Q3 25 | -18.1% | -118.1% | ||
| Q2 25 | 9.1% | -103.6% | ||
| Q1 25 | 5.0% | -86.6% | ||
| Q4 24 | 10.2% | — | ||
| Q3 24 | 21.7% | -136.4% | ||
| Q2 24 | 28.5% | -182.2% | ||
| Q1 24 | 28.1% | -138.9% |
资本支出强度BGSFLAB
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.4% | 4.5% | ||
| Q2 25 | 0.0% | 8.7% | ||
| Q1 25 | 0.1% | 12.4% | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | 0.0% | 10.2% | ||
| Q2 24 | 0.0% | 8.6% | ||
| Q1 24 | 2.0% | 1.7% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BGSF
| Contract Field Talent | $21.4M | 97% |
| Other | $595.0K | 3% |
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
